Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product

COPENHAGEN, Denmark, Oct. 16, 2023 (GLOBE NEWSWIRE) — Copenhagen Infrastructure Partners has reached final close for its two new funds, CI Advanced Bioenergy Fund I (CI ABF I) and CI Green Credit Fund I (CI GCF I) with total LP commitments of EUR ~2bn. 2023 has been a record year

Wuhan, China – October 16, 2023 – Atos has renewed its Value-Added Telecommunication Services licenses (VATS licenses) in China, enabling it to run world class digital services and data centers across the country. Atos Cloud Computing has retained the licenses since 2019, being the first authorized foreign-funded company to operate

Smart City Expo World Congress BARCELONA, Spain, Oct. 15, 2023 (GLOBE NEWSWIRE) — Smart City Expo World Congress (SCEWC), the international summit on cities and smart urban solutions, organized by Fira De Barcelona, will hold its biggest edition to date in 2023. Taking place from November 7th to 9th, the

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS) Maintenance treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved HiSCR75 at week 24, increasing the landmark